Introduction

Thymic involution and intensive chemotherapy result in prolonged CD4
þ T-cell depletion and impaired T-cell immunity in patients with cancer receiving autologous stem cell transplantation (SCT). [1] [2] [3] Adoptive transfer of anti-CD3/ anti-CD28 (CD3/CD28)-expanded T cells 4 induces lymphocytosis in patients with relapsed non-Hodgkin's lymphoma following autologous SCT, 5 and induces molecular remission of chronic myelogenous leukemia. 6 More specifically, adoptive therapy with ex vivo-activated CD4 þ T helper type 1 (Th1) cells with a diverse T-cell repertoire may accelerate immune reconstitution, improve engraftment of adoptively transferred cytotoxic T lymphocytes and augment vaccine response in the setting of SCT. Infusions of autologous CD3/ CD28-expanded CD4 þ T cells have yielded considerable success in reconstituting CD4
þ T-cell function in human immunodeficiency virus (HIV)-infected patients. 7 Cytokine immunotherapy using interleukin (IL)-2 with or without adoptive immunotherapy has also been shown to be beneficial in patients with hematological malignancies. 8, 9 IL-15, an IL-2-like common g chain signaling cytokine with wide tissue distribution, 10 serves as another promising candidate for immunotherapy as it also promotes T-cell proliferation 11 and, distinct from IL-2, inhibits activation-induced cell death (AICD). 12 IL-15 improves immune reconstitution in allogeneic bone marrow transplantation, 13 and counteracts the increased apoptosis of T cells observed in subjects receiving autologous peripheral blood progenitor cell transplantation. 14 The present study aims to examine the regulatory effect of IL-15 on phenotype and effector function of CD3/ CD28-activated CD4 þ T cells in terms of activation marker expression and cytokine production, relevant to the possible clinical use of IL-15-treated CD3/CD28-activated CD4 þ T cells for adoptive immunotherapy in patients with relapsed hematological malignancies. We also sought to determine the effect of IL-15-treated CD3/CD28-activated CD4
þ T cells on proliferation of autologous peripheral blood lymphocytes (PBL). We found in this study that IL-15 further enhances both Th1 and Th2 cytokine production and promotes the acquisition of CD25 þ /CD45RO þ /CD62L À effector-memory phenotype in CD3/CD28-activated CD4 þ T cells. However, pretreat-ment of CD3/CD28-activated CD4 þ T cells with IL-15 downregulates autologous PBL proliferation further than CD3/CD28-activated CD4 þ T cells alone.
Materials and methods
Purification of CD4
þ T cells PBL were obtained using Ficoll-Hypaque density gradient centrifugation from normal adult volunteers under informed consent, with the pre-approval of the study by Medical Ethics and Human Clinical Trial Committee of the Chang Gung Memorial Hospital. CD4 þ cells were enriched from PBL with an isolation kit containing a cocktail of CD8, CD11b, CD16, CD19, CD36 and CD56 antibodies (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). The separation was performed with LS þ columns (Miltenyi Biotech), according to the manufacturer's instruction. The purity of CD4 þ T cells (checked by TCR ab staining) was confirmed by FACS to be greater than 95%.
Preparation of cell culture
Purified CD4
þ T cells were then resuspended in RPMI with 10% fetal calf serum (FCS) at a concentration of 1 Â 10 6 /ml and placed in six-well plate precoated with or without anti-CD3 MoAb (1 mg/ml; BD Biosciences, San Diego, CA, USA) plus anti-CD28 (1 mg/ml; BD Biosciences), in the presence or absence of IL-15 (10 ng/ml; PeproTech Inc, Rocky Hill, NJ, USA) for a 7-day incubation. Interleukin-15 was added every other day during the incubation. The cultured cells were then harvested and counted with the viability determined by Trypan blue exclusion under microscopy.
Th1/Th2 cytokine determination Th1 and Th2 cytokines including IL-2, IL-4, IL-5, IL-10, IFN-g and TNF-a were quantified simultaneously using a human Th1/Th2 cytokine cytometric bead array (CBA) kit. (BD Pharmingen, San Diego, CA, USA). These assay kits provided a mixture of six microbead populations with distinct fluorescent intensities (FL-3) and were precoated with capture antibodies specific for each cytokine. A 50 ml portion of culture supernatant or the standard cytokines provided was added to the premixed microbeads in 12 mm Â 75 mm Falcon tubes (BD). After the addition of 50 ml of a mixture of phycoerythrin (PE)-conjugated antibodies against the cytokines, the mixture was incubated for 3 h in the dark at room temperature. This mixture was washed and centrifuged at 500 g for 5 min and the pellet resuspended in 300 ml of wash buffer. The FACSCalibur flow cytometer (BD Pharmingen) was calibrated with setup beads and 3000 events were acquired for each sample. Individual cytokine concentrations were indicated by their fluorescent intensities (FL-2) and were computed using the standard reference curve of CellQuest and CBA software (BD Pharmingen). 
Effect of cultured CD4
þ T cells on autologous T-cell proliferation CD4 þ T cells cultured under various conditions were tested for their ability to influence the proliferation of autologous PBL in the presence of polyclonal activation. Autologous PBLs (1 Â 10 6 cells/ml) were pulsed with 1 mM fluorescent dye carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Montlucon, France) in 2% FCS medium and were stimulated with plate-bound anti-CD3 (5 mg/ml) and anti-CD28 (5 mg/ml) in the presence or the absence of previously cultured CD4
þ T cells at a ratio of 1:1. In some experiments, the cultured CD4 þ T cells were prevented from directly contacting the CFSE-labeled PBLs by addition to a upper chamber of 6.5-mm Transwells with 0.4 mm pore size membranes (Costar, Corning, NY, USA), and stimulated by addition of CD3/CD28 Dynabeads (Dynal Biotech, Invitrogen Corp., CA, USA), added directly to the upper well. Cultures were incubated for 4 days at 371C in 5% CO 2 . After culture, cells were harvested and stained with anti-CD25-PE, anti-CD8-PE, Annexin-V-PE, and analyzed by flow cytometry using a FACScan. Cell division of PBL can be analyzed using flow cytometric measurement of CFSE dye dilution according to Lyons et al.
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Statistics Paired Student's t-test was performed to compare the difference of responses between different treatments from the same sample (calculated by SPSS 9.0 software). The data are presented as mean7standard error of mean (s.e.m.). Groups being compared were considered significantly different if the P-value was less than 0.05.
Results
Effect of interleukin-15 on cell recovery and CD45RO, CD25 and CD62L expression of CD3/CD28-activated CD4 þ T cells The percent of viable CD4 þ T-cell recovery as calculated by (viable cell count on day 7/viable cell count on day 1) Â 100 was 5776% in unstimulated CD4 þ T cells, increasing to 109719% (P ¼ 0.025, n ¼ 8) for CD3/CD28-activated CD4 þ T cells, and further to 174720% with IL-15-treated CD3/CD28-stimulated CD4 þ T cells (P ¼ 0.001, n ¼ 8). Figure 1 shows the percent expression of CD45RO, CD25 and CD62L on CD4 þ T cells before (Fresh) and after stimulation with CD3/CD28 and/or IL-15. No difference for CD45RO and CD62L expression was found between freshly isolated CD4 þ T cells and CD4 þ T cells cultured in the media for 7 days (P ¼ 0.88 and P ¼ 0.56, respectively). Freshly isolated CD4 þ T cells did show higher CD25 expression (2072 vs 971% in Media, P ¼ 0.004), possibly owing to transient activation by bead separation. CD45RO (Po0.001) and CD25 (P ¼ 0.004), but not CD62L (P ¼ 0.46) expression was enhanced with CD3/CD28 activation. Compared to CD3/CD28 stimulation alone, addition of IL-15 further increased CD25 (P ¼ 0.011) and CD45RO expression (P ¼ 0.005), whereas %CD62L expression on CD3/CD28-activated CD4 þ T cells was not influenced by IL-15 (P ¼ 0.168). Figure 2 shows þ T cells cultured in media (Media), anti-CD3 (1 mg/ml) plus anti-CD28 (1 mg/ml) (CD3/CD28) and anti-CD3 (1 mg/ml) plus anti-CD28 (1 mg/ml) in the presence of interleukin-15 (IL-15) (10 ng/ml) (CD3/ CD28 þ IL-15) (n ¼ 8). The horizontal line in the box represents the median, the lower and upper quantiles (25 and 75%). The 10th and 90th percentiles were used as whiskers, with values outside the range plotted individually. þ T cells cultured in media (Media), anti-CD3 (1 mg/ml) plus anti-CD28 (1 mg/ml) (CD3/CD28), and anti-CD3 (1 mg/ml) plus anti-CD28 (1 mg/ml) in the presence of interleukin-15 (IL-15) (10 ng/ml) (CD3/CD28 þ IL-15). The isotype controls are presented as shaded areas. þ T-cell culture in anti-CD3 (1 mg/ml) and anti-CD28 (1 mg/ml) (CD3/CD28), or in the presence of both anti-CD3 (1 mg/ml) and anti-CD28 (1 mg/ml) and IL-15 (10 ng/ml) (CD3/CD28 þ IL-15) (n ¼ 8). The horizontal line in the box represents the median, the lower and upper quantiles (25 and 75%). The 10th and 90th percentiles were used as whiskers, with values outside the range plotted individually.
Interleukin Effect of CD3/CD28-activated CD4 þ T cells on autologous peripheral blood lymphocytes proliferation -regulation with interleukin-15 Prelabeling PBL with CFSE before activation and culturing them with unlabeled cultured CD4 þ T cells permitted monitoring the proliferation of PBL specifically (Figure 4) . Unstimulated PBL showed minimal proliferation ( Figure  4Aa ), which was unaffected by addition of autologous
þ T cells (data not shown). Upon stimulation with plate-bound CD3/CD28, 76.67 1.6% (n ¼ 8) of autologous PBL co-cultured with unstimulated CD4 þ T cells underwent 2-5 cycles of division and were used as controls (Figure 4Ac ). The suppressive effect on PBL proliferation was observed with addition of CD3/ CD28-activated CD4 þ T cells (63.474.8%, P ¼ 0.014 compared to controls). Addition of CD3/CD28 þ IL-15-activated CD4 þ T cells further inhibited PBL proliferation (52.573.9%, P ¼ 0.002 compared to CD3/CD28-activated
cells). CD25 MFI on autologous PBLs was also downregulated with addition of CD3/CD28 þ IL-15-activated CD4
þ T cells (158724, P ¼ 0.002), compared to levels with addition of CD3/CD28-activated CD4 þ T cells (188729). Similar suppressive effects of CD3/CD28 þ IL-15-activated CD4 þ T cells were seen on autologous CD8 þ PBL proliferation ( Figure 4B ).
Transwell separation prevents acquisition of regulatory function of CD3/CD28 þ IL-15-activated CD4 þ T cells To determine whether the CD3/CD28 þ IL-15-activated CD4 þ T cells mediated their suppressive effect through cell-cell contact, cultured CD4 þ T cells were added to the CFSE-labeled autologous PBL either in the same well or separated from autologous PBL in a 0.4-mm pore size Transwell. As shown in Figure 5 , interfering with cell-cell Increased apoptosis of CD3/CD28 þ IL-15-activated CD4 þ T cells following co-culture with peripheral blood lymphocytes upon TCR ligation As shown in Figure 6 , staining with Annexin-V-PE and CFSE revealed that proliferating autologous PBL alone upon stimulaton with plate-bound CD3/CD28 did not express Annexin-V to any significant degree (Figure 6a and  b) , whereas co-culture experiments revealed that apoptosis occurred predominantly in the added CD4 þ T cells rather than in autologous PBL (Figure 6c-e) The percent expression of Annexin-V on untreated CD4 þ T cells was comparable to that on CD3/CD28-activated CD4 þ T cells (36.072.5 vs 38.573.4%, P ¼ 0.52). However, a greater degree of Annexin-V expression was found on CD3/ CD28 þ IL-15-activated CD4 þ T cells, compared to that on CD3/CD28-activated CD4 þ T cells (55.373.1 vs 38.573.4%, P ¼ 0.005).
Discussion
Effective ex vivo T-cell expansion with CD3/CD28 may compensate for the lack of available T cells for adoptive transfer in heavily pretreated patients receiving autologous SCT. 4, 16 Further manipulation in culture conditions by adding cytokines may enhance Th1 or Th2 CD4
þ T-cell function. With relevance to adoptive immunotherapy with ex vivo IL-15-supplemented CD3/CD28-activated CD4 þ T cells in patients following autologous SCT, we demonstrated in the present study that IL-15 enhances effector functions of CD3/CD28-activated CD4 þ T cells in terms of activation marker expression and Th1/Th2 cytokine production. Interleukin-15 also enhanced the regulatory function of CD3/CD28-activated CD4 þ T cells by further inhibiting autologous PBL and CD8 þ subset proliferation. We found that IL-15 further enhanced CD45RO and CD25 expression on CD3/CD28-activated CD4 þ T cells, confirming previous reports. 12,17 CD62L, an adhesion molecule that mediates lymphocyte interactions with vascular endothelium for homing, however, was downregulated by IL-15. Loss of CD62L expression on CD4 þ T cells has been associated with effector memory transformation 18 and activation-induced apoptosis.
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In agreement with Niedbala et al., 20 cytokine production studies revealed that IL-15 enhanced both Th1 (IFN-g and TNF-a) and Th2 cytokines (IL-5 and IL-10) of CD3/CD28-activated CD4 þ T cells, but not IL-2 and IL-4 production. Previous studies demonstrated that CD62-negative and -positive subpopulations of human CD45RO þ CD4 þ T cells represent characteristics of Th1 and Th2, respectively. 21, 22 In this regard, IL-15 may preferentially induce a Th1 phenotype on CD3/CD28 CD4 þ T cells, which is considered to have greater AICD susceptibility than Th2 subsets. 23, 24 The increased inhibitory effect of CD3/CD28-activated CD4 þ T cells on proliferation of autologous PBLs upon TCR ligation over the unstimulated CD4 þ T cells was further enhanced by pretreatment with IL-15. Proliferation by CD8
þ PBL subsets was similarly suppressed. We found that IL-15 further enhanced CD25 expression on CD3/ CD28-activated CD4 þ T cells, suggesting a possible expansion of CD4 þ CD25 high T cells with potent regulatory function. 25, 26 On the other hand, the cytokine production profile of CD3/CD28 þ IL-15-activated CD4 þ T cells (high IFN-g, IL-5, IL-10, but no IL-2 and IL-4) resembled that of T-regulatory 1 (Tr1) cells, the regulatory functions of which are IL-10 mediated in a contact-independent fashion. 27 Transwell studies demonstrated that IL- 15 In contrast to studies in the mouse demonstrating high levels of CD62L by CD4 þ CD25 þ regulatory T cells 31 and the unique ability of CD62L high -expressing regulatory T cells to protect from acute GVHD, 32 CD62L does not necessarily identify human regulatory T cells. 25, 26 We found an enhanced regulatory function of CD3/CD28 þ IL-15-treated CD4 þ T cells with lower CD62L expression. Thus, the fluorescent intensity of CD62L expression, unlike that of CD25, may not correlate with regulatory T-cell function in vitro.
Activation-induced cell death is a major impediment in CD4 adoptive immunotherapy in cancer 33 and accounts for lymphopenia observed in the setting of IL-2 immunotherapy. 34 Taken together, IL-15 is effective in upregulating CD25/ CD45RO expression and enhancing the regulatory function of CD3/CD28-activated CD4 þ T cells. The susceptibility to AICD of CD3/CD28 þ IL-15-activated CD4 þ T cells suggests that they may not provide additional benefits on immune reconstitution compared to CD3/CD28-stimulated cells alone in patients with relapsed Hodgkin's or nonHodgkin's lymphoma receiving autologous stem cell transplant. However, the IL-15-treated CD3/CD28-activated cells with enhanced regulatory T function may prove useful to prevent autoimmunity, as they also suppressed CD8 þ T-cell response. 36 Further work will be needed to clarify the molecular mechanisms of IL-15-induced T-regulatory function. 
